Adriamycin in Combination and in Combined Treatment Modalities.

The paper reviews the current strategic approach of the Istituto Nazionale Tumori of Milan with adriamycin (ADM) in combination with other drugs as well as in combined treatment modalities for various neoplasias of adults and children. The preliminary results obtained during the past four years in malignant lymphomas, acute leukemias, carcinoma of the breast, and neuroblastoma are reported. With the exception of the group of malignant lymphomas treated with a quintuple drug regimen (MABOP), none of the patients admitted the different trials had received chemotherapy. Most studies were controlled with random allocation to two different combinations. Cross over was carried out on relapse. In advanced Hodgkin's disease, non-Hodgkin's lymphomas, mammary carcinoma, soft tissue sarcomas, embryonal carcinoma of testicle, ovarian carcinoma, and multiple myeloma the main purpose of the study was to develop two independent non cross resistant combinations to be used sequentially in subsequent trials. There is a preliminary evidence that this is being obtained in Hodgkin's disease (ABVD vs. MOPP), in non Hodgkin's lymphomas (ABP vs. CVP) and carcinoma of the breast (ADM + VCR vs. CMF). In the other groups the patients were too few to permit conclusions. In acute lymphoblastic leukemia, in the leukemic phase of non-Hodgkin's lymphomas as well as in the group of solid tumors of children, combination chemotherapy and combined treatment modalities were not designed in a controlled fashion. ADM was introduced in all treatments because of its definite activity when employed as a single agent in refractory disease. Few therapeutic results are as yet available since most studies were started in 1974. However, the remission rate observed in the limited group of acute leukemias treated with ADM + VCR + prednisone is worth noting. The wide spectrum of activity of ADM justifies its use in several protocols of combination chemotherapy and in combined treatment modalities. With both full and reduced regimens drug tolerance was good, and in practically all studies more than 80 % of the optimal dose of ADM could be administered. All trials were properly designed to avoid a total dose of ADM exceeding 550–600 mg/m2 since cardiomyopathy (reversible) was observed in 2 patients after 600 mg/m2.

Download Full-text

The efficiency of different combined treatment programs (combination chemotherapy-radiotherapy) used for stage I–II Hodgkin's disease

Radiotherapy and Oncology ◽

10.1016/s0167-8140(87)80164-0 ◽

1987 ◽

Vol 8 (2) ◽

pp. 113-122 ◽

Cited By ~ 4

Author(s):

G.D. Baysogolov ◽

S.V. Shakhtarina

Keyword(s):

Combination Chemotherapy ◽

Hodgkin's Disease ◽

Hodgkin’S Disease ◽

Combined Treatment ◽

Stage I ◽

Treatment Programs

Download Full-text

Cis-Dichlorodiammineplatinum (II), VP 16-213, and Prednisone (Dvp Regimen) in the Treatment of Pretreated Advanced Malignant Lymphomas

Tumori Journal ◽

10.1177/030089168206800611 ◽

1982 ◽

Vol 68 (6) ◽

pp. 515-518

Author(s):

Vinicio P. Fosser ◽

Luigi Salvagno ◽

Romana Segati ◽

Giovanni L. Pappagallo ◽

Eros Ferrazzi ◽

...

Keyword(s):

Bone Marrow ◽

Combination Chemotherapy ◽

Hodgkin's Disease ◽

Partial Remission ◽

Hodgkin’S Disease ◽

Bone Marrow Involvement ◽

Malignant Lymphomas ◽

Schedule Interval ◽

Heavily Pretreated ◽

Pretreated Patients

Eighteen evaluable patients with advanced malignant lymphoma were treated with a combination of cis-dichlorodiammineplatinum (II) (50 mg/m2 i.v. on day 1), VP 16-213 (100 mg/m2 i.v. on days 1, 3, 5), and prednisone (50 mg/m2 per os on days 1–5), recycling every 2 weeks. All patients were previously pretreated. There were 3 complete remissions (patients with Hodgkin's disease), and 4 partial remission (2 patients with Hodgkin's and 2 with non-Hodgkin's lymphoma), for a median duration of 8 weeks. In addition, 2 minor responses (patients with Hodgkin's disease) were observed. Vomiting and myelosuppression were the most prominent toxic effects. In most heavily pretreated patients, myelosuppression was moderate to severe: in these patients and in patients with bone marrow involvement, a schedule interval of 3 weeks should be more appropriate. Nephrotoxicity was minimal. This combination chemotherapy showed some activity in the management of advanced malignant lymphomas; further studies in this area are justified.

Download Full-text

The classification and terminology of malignant lymphomas other than Hodgkin’s disease (non-Hodgkin’s lymphomas — NHL)

Biopsy Pathology of the Lymphoreticular System ◽

10.1007/978-1-4899-3396-6_5 ◽

1983 ◽

pp. 119-127 ◽

Cited By ~ 1

Author(s):

Dennis H. Wright ◽

Peter G. Isaacson

Keyword(s):

Hodgkin's Disease ◽

Hodgkin’S Disease ◽

Malignant Lymphomas ◽

Hodgkin's Lymphomas

Download Full-text

Comparison of Radiological Findings in Children with Hodgkin's Disease and Non-Hodgkin's Lymphomas at Disease Presentation.

Tumori Journal ◽

10.1177/030089167506100605 ◽

1975 ◽

Vol 61 (6) ◽

pp. 533-545

Author(s):

Renato Musumeci ◽

Ronald A. Castellino ◽

Franca Fossati Bellani ◽

Marco Gasparini

Keyword(s):

Hodgkin's Disease ◽

Hodgkin’S Lymphoma ◽

Hodgkin’S Disease ◽

Hodgkin's Lymphoma ◽

Diagnostic Tools ◽

Radiological Findings ◽

Malignant Lymphomas ◽

Non Hodgkin’S Lymphoma ◽

Non Hodgkin's Lymphoma ◽

Hodgkin's Lymphomas

From January 1968 to March 1975, 115 patients with malignant lymphomas, all aged under 15 years, were admitted to the Istituto Nazionale Tumori of Milan: 57 had Hodgkin's disease (mean age 9.7 yrs) and 58 non-Hodgkin's lymphomas (mean age 7.7 yrs). In this group of consecutive unselected and untreated patients the incidence of lesions radio-logically evident at disease presentation was comparatively evaluated in relation to histology. 36 cases underwent a subsequent diagnostic laparotomy with splenectomy. Chest X-ray was performed in all patients. It proved to be pathologic in 44 % of patients with Hodgkin's disease (mediastinal adenopathies were present in all cases). Pulmonary lesions were documented in 5 %, pleural in 2 % and skeletal in 2 %. Lymphography showed retroperitoneal involvement in 16 % with Hodgkin's disease and in 29 % with malignant lymphomas; radiological findings were confirmed by laparotomy in 35/36 cases. Skeletal survey proved to be abnormal in only 2 % of Hodgkin's compared to 18 % of non-Hodgkin's lymphomas. All lesions were clinically symptomatic. Intestinal involvements (small bowel and colon), which were always symptomatic, were present in 15 patients with non-Hodgkin's lymphoma (26%). IVP showed direct involvement of kidneys in 2 patients with non-Hodgkin's lymphoma. The comparison of radiological findings in the two groups of patients confirm that non-Hodgkin's lymphomas have a more aggressive initial spread: 43 % of patients were classified as stage IV at disease presentation. At the same time, our data prove that some of these diagnostic tools are of scant use when performed as a screening procedure for occult lesions.

Download Full-text

Histologic and Cytologic Liver Changes in 120 Patients with Malignant Lymphomas

Tumori Journal ◽

10.1177/030089167806400105 ◽

1978 ◽

Vol 64 (1) ◽

pp. 45-53 ◽

Cited By ~ 11

Author(s):

Anton Roth ◽

Krsto Kolarić ◽

Mara Dominis

Keyword(s):

Liver Biopsy ◽

Hodgkin's Disease ◽

Hodgkin’S Disease ◽

Liver Steatosis ◽

Clinical Staging ◽

Liver Involvement ◽

Percutaneous Liver Biopsy ◽

Malignant Lymphomas ◽

Liver Changes ◽

Hodgkin's Lymphomas

The purpose of this study was to determine the frequency of liver involvement in malignant lymphomas. Non-specific liver changes were also registered. Percutaneous liver biopsy was performed on 120 patients with untreated malignant lymphomas. There were 38 patients with Hodgkin's disease, 42 with histiocytic and 40 with lymphocytic lymphomas. AH the biopsy specimens were histologically and cytologically analyzed. Positive liver findings (lymphomatous infiltration) were observed in 27.5% of patients with lymphocytic, 23.8% with histiocytic lymphomas, and 7.8% with Hodgkin's disease. Liver involvement in non-Hodgkin's lymphomas was significantly higher (P < 0.025) than in Hodgkin's disease. In the whole group of patients, there were non-specific liver changes: 23 chronic persistent hepatitis, 5 aggressive hepatitis, 9 liver steatosis and 4 liver hemosiderosis. Based on these results, it can be concluded that liver involvement with lymphomatous tissue is more common in non-Hodgkin's lymphomas. Knowledge of this is relevant for clinical staging and the treatment program. These findings also confirm that percutaneous liver biopsy is a valuable diagnostic procedure in the staging of malignant lymphomas.

Download Full-text